Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Endometrial Cancer | Research article

The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Previous studies conducted on the association between diabetes and the risk of endometrial cancer have reported controversial results that have raised a variety of questions about the association between diabetes and the incidence of this cancer. Thus, the aim of this systematic review and meta-analysis was to more precisely estimate the effect of diabetes on the risk of endometrial cancer incidence.

Methods

All original articles were searched in international databases, including Medline (PubMed), Web of sciences, Scopus, EMBASE, and CINHAL. Search was done from January 1990 to January 2018 without language limitations. Also, logarithm and standard error logarithm relative risk (RR) were used for meta-analysis.

Results

A total of 22 cohort and case-control studies were included in this meta-analysis, of which 14 showed statistically significant associations between diabetes and risk of endometrial cancer. Diabetes was associated with increased risk of endometrial cancer (RR = 1.72, 95% CI 1.48–2.01). The summary of RR for all 9 cohort studies was 1.56 (95% CI 1.21–2.01), and it was 1.85 (95% CI 1.53–2.23) for 13 case control studies. The summary of RR in hospital-based studies was higher than other studies. Thirteen of the primary studies-controlled BMI as a confounding variable, and the combined risk of their results was 1.62 (95% CI 1.34–1.97).

Conclusions

Diabetes seems to increases the risk of endometrial cancer in women, and this finding can be useful in developing endometrial cancer prevention plans for women having diabetes.
Literature
1.
Lortet-Tieulent J, et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2017;110(4):354–61.CrossRef
2.
Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008–12.CrossRef
3.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33–64.CrossRef
4.
Luo J, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432.CrossRef
5.
Anderson KE, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2001;10(6):611–6.PubMed
6.
Lindemann K, et al. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98(9):1582.CrossRef
7.
Ali A. Risk factors for endometrial cancer. Ceska Gynekol. 2013;78(5):448–59.PubMed
8.
Friberg E, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.CrossRef
9.
Knottnerus A, Tugwell P. STROBE—a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. 2008;61(4):323.
10.
Von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.CrossRef
11.
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9(1):1–30.CrossRef
12.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef
13.
Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRef
14.
Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1998;316(7129):470–1.
15.
Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.CrossRef
16.
AlHilli M, et al. The impact of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2015;137:156–7.CrossRef
17.
Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):276–80.CrossRef
18.
Lambe M, et al. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011;22(8):1163–71.CrossRef
19.
Coughlin SS, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160–7.CrossRef
20.
Folsom AR, et al. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol. 2004;94(3):740–5.CrossRef
21.
Terry P, et al. Lifestyle and endometrial cancer risk: a cohort study from the Swedish twin registry. Int J Cancer. 1999;82(1):38–42.CrossRef
22.
Brinton LA, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–25.CrossRef
23.
Friedenreich CM, et al. Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2384–95.CrossRef
24.
Inoue M, et al. A case-control study on risk factors for uterine endometrial Cancer in Japan. Cancer Sci. 1994;85(4):346–50.
25.
Lucenteforte E, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer. 2007;97(7):995.CrossRef
26.
Parazzini F, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer. 1999;81(4):539–42.CrossRef
27.
Rubin GL, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990;162(1):148–54.CrossRef
28.
Salazar-Martínez E, et al. Case–control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control. 2000;11(8):707–11.CrossRef
29.
Saltzman BS, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. 2007;167(5):607–14.
30.
Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148(3):234–40.CrossRef
31.
Soliman PT, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–81.CrossRef
32.
Wartko PD, et al. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017;28(8):819–28.CrossRef
33.
Weiderpass E, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11(2):185–92.CrossRef
34.
Weiss JM, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol. 2006;164(1):56–62.CrossRef
35.
Tsilidis KK, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj. 2015;350:g7607.CrossRef
36.
Austin MA, et al. The effect of response bias on the odds ratio. Am J Epidemiol. 1981;114(1):137–43.CrossRef
37.
Heid I, et al. On the potential of measurement error to induce differential bias on odds ratio estimates: an example from radon epidemiology. Stat Med. 2002;21(21):3261–78.CrossRef
38.
Nemes S, et al. Bias in odds ratios by logistic regression modelling and sample size. BMC Med Res Methodol. 2009;9(1):56.CrossRef
39.
Clayton D, Hills M, Pickles A. Statistical models in epidemiology, vol. 161. Oxford: Oxford university press; 1993.
40.
Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet. 2002;359(9304):431–4.CrossRef
41.
Wacholder S, et al. Selection of controls in case-control studies: II. Types of controls. Am J Epidemiol. 1992;135(9):1029–41.CrossRef
42.
Arima R, et al. Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication. Gynecol Oncol. 2017;147(3):678–83.CrossRef
43.
Arima R, et al. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017;146(3):636–41.CrossRef
44.
Park Y, Colditz GA. Diabetes and adiposity: a heavy load for cancer. Lancet Diabetes Endocrinol. 2018;6(2):82–3.CrossRef
45.
Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.CrossRef
46.
Murphy LJ. Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol. 1994;48(5–6):419–23.CrossRef
47.
Corocleanu M. Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol. 1993;20(4):254–8.PubMed
48.
Thiet M-P, Osathanondh R, Yeh J. Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal müllerian tract. Am J Obstet Gynecol. 1994;170(1):152–6.CrossRef
49.
Ordener C, et al. Epidermal growth factor and insulin induce the proliferation of Guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod. 1993;49(5):1032–44.CrossRef
50.
Friberg E, et al. Coffee drinking and risk of endometrial cancer—a population-based cohort study. Int J Cancer. 2009;125(10):2413–7.CrossRef
Metadata
Title
The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis
Publication date
01-12-2019
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5748-4

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Case report

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review

Study protocol

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study

Research article

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis

Research article

Resilience and associated factors among Chinese patients diagnosed with oral cancer

Research article

Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling

Research article

TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits